INCB161734-101: what clinicians are saying
INCB161734; INCB161734 plus cetuximab; INCB161734 plus retifanlimab in KRAS G12D-mutated advanced or metastatic solid tumors · NCT06179160 ↗ · Phase 1 · Incyte Corporation
For INCB161734-101, a speaker described in the sources as presenting the trial favors cetuximab-combination development in CRC given limited single-agent activity, without randomized proof of benefit. Medical oncologists consider chemotherapy combinations feasible in PDAC; a speaker tentatively favors FFXN for potentially lower GI toxicity. Durability remains uncertain. The sources place INCB161734 phase 1 PDAC findings at ASCO GI 2026, with updated PDAC combination results at ESMO 2026.
Created with AI · how we check it
- edition 1
- commentary checked Nov 20, 2026
- 32 verified statements
This edition $750, with MCP access for your AI agent. Get this report
6 findings, and what sits behind each
01. CRC: speakers note cetuximab combo activity; most see combos as needed
No named clinician · accounts and unnamed speakers · 9 statements from 3 speakers in 3 sources, all podcasts or videos · 4 passages
Limitations recorded: 4.
Draws on: Secondary endpoint: Objective Response Rate (ORR), The comparison, Population and setting, Design and conduct, Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs), Primary endpoint: Number of participants with TEAEs leading to dose modification or discontinuation, Secondary endpoint: Disease Control Response (DCR), Safety and tolerability.
02. PDAC phase 1 combos: some clinicians see feasibility; a speaker weighs GI trade-offs
6 of the report's 9 cited clinicians · 10 statements from 8 speakers in 9 sources · 9 passages
Limitations recorded: 4.
Draws on: Safety and tolerability, Secondary endpoint: Objective Response Rate (ORR), The comparison, Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs), Secondary endpoint: Disease Control Response (DCR), Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs), Primary endpoint: Number of participants with TEAEs leading to dose modification or discontinuation, Population and setting, Design and conduct.
03. PDAC phase 1: most speakers highlight responses; a clinician awaits PFS/OS medians
5 of the report's 9 cited clinicians · 13 statements from 7 speakers in 8 sources · 8 passages
Limitations recorded: 5.
Draws on: Secondary endpoint: Objective Response Rate (ORR), Safety and tolerability, Population and setting, The comparison, Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs), Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs), Primary endpoint: Number of participants with TEAEs leading to dose modification or discontinuation, Secondary endpoint: Duration of Response (DOR), Design and conduct.
04. KRAS trial choice: a speaker asks why QTX3034 was chosen over other KRAS trials
No named clinician · accounts and unnamed speakers · 2 statements from 1 speaker in 2 sources · 2 passages
Limitations recorded: 3.
05. KRAS: most speakers welcome development; a clinician expects a PDAC standard of care
5 of the report's 9 cited clinicians · 7 statements from 6 speakers in 6 sources · 6 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Secondary endpoint: Objective Response Rate (ORR), Secondary endpoint: Disease Control Response (DCR), Secondary endpoint: Duration of Response (DOR).
06. Appendix cancer: a clinician proposes a trial, ideally with a PD1 inhibitor
1 of the report's 9 cited clinicians · 1 statement from 1 speaker in 1 source · 1 passage
Limitations recorded: 1.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 6
No named clinician · accounts and unnamed speakers
CRC: speakers note cetuximab combo activity; most see combos as needed
9 statements from 3 speakers in 3 sources, all podcasts or videos
3 of the 3 named speakers in this finding hold this view; 2 of them hold its caveat, “most see combos as needed”
- 9
- statements
- 4
- passages
- 3
- sources
- 3
- speakers
What the statements areViews 6Questions and uncertainty 0Clinical experience 0Comparisons 2Restated results and context 1Statement-to-passage links (a passage can back several statements)Supporting a statement 10Giving context 1Recorded with the findingLimitations: 4
3 podcasts and video
Draws on: Secondary endpoint: Objective Response Rate (ORR), The comparison, Population and setting, Design and conduct, Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs), Primary endpoint: Number of participants with TEAEs leading to dose modification or discontinuation, Secondary endpoint: Disease Control Response (DCR), Safety and tolerability.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
Abbreviations (15)
ASCO, American Society of Clinical Oncology; CRC, colorectal cancer; DCR, disease control rate; DLT, dose-limiting toxicity; DOR, duration of response; ESMO, European Society for Medical Oncology; GI, gastrointestinal; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; ORR, objective response rate; OS, overall survival; PDAC, pancreatic ductal adenocarcinoma; PFS, progression-free survival; SAE, serious adverse event.
The full INCB161734-101 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians need to see on activity and tolerability from larger INCB161734–cetuximab cohorts and chemotherapy combinations to build on phase 1b findings in heavily pretreated KRAS G12D-mutant metastatic colorectal cancer?
From findings F1 (9 statements from 3 speakers in 3 sources) and F5 (7 statements from 6 speakers in 6 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 28commentary sources screened
- 18sources cited by verified statements
- 16named in screened sources
- 16speakers cited in the report
- 13cited speakers with a verified identity
9 cited clinicians, speakers with a confirmed clinical role, of them 9 physicians. By role and specialty:
- 7 physician, Medical oncology
- 1 physician, specialty not confirmed
- 1 physician, Gastroenterology
Also in the sources: 1 organizational or shared account, not counted as people.
- 32verified statements, each linked to its source
- 16of them from speakers with a confirmed clinical role
- 6findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 32 | Paid |
| Who said each statement: the cited speakers | 16 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 9 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 13 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 16 | Free |
| Sources with links | 18 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
15 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs) | 1 | 1 |
| Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs) | 3 | 3 |
| Primary endpoint: Number of participants with TEAEs leading to dose modification or discontinuation | 2 | 2 |
| Secondary endpoint: INCB161734 pharmacokinetic (PK) in Plasmano commentary found | 0 | 0 |
| Secondary endpoint: Objective Response Rate (ORR) | 12 | 10 |
| Secondary endpoint: Disease Control Response (DCR) | 3 | 3 |
| Secondary endpoint: Duration of Response (DOR) | 1 | 1 |
| Population and setting | 6 | 6 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 8 | 7 |
| Safety and tolerability | 8 | 8 |
| Design and conduct | 5 | 4 |
| ctDNA response and possible KRAS copy-number resistance | 5 | 3 |
| Survival follow-up and six-month PFS reporting | 2 | 2 |
| Trial visibility and choice among KRAS studies | 2 | 2 |
| Forward-looking PDAC positioning and development expectations | 7 | 6 |
| Proposed appendix-cancer study with PD1 blockade | 1 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
32 verified statements from 18 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 9 statements · 28% | ||||
| YouTube | 9 | 3 | 3 | |
| Posts · 23 statements · 72% | ||||
| X threads | 23 | 15 | 24 | |
| Bluesky threads | 0 | 0 | 1 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 15 / quarter
- Screened window
- Dec 21, 2023 → Nov 2, 2026
- Cited window
- Dec 21, 2023 → Nov 2, 2026
- Retrieved
- Nov 20, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Registry
- NCT06179160
- Study IDs
- INCB161734-101 · 2023-507091-47-00 (EU CT Number)
- Sponsor
- Incyte Corporation
- Design
- Phase 1 · Interventional, non randomized, sequential
- Status
- Recruiting
- Enrollment
- 710 estimated
- Registered
- 2023-12-21
- Start
- 2024-01-04 actual
- Primary completion
- 2027-01-01 estimated
- Primary endpoints
- Number of participants with Dose Limiting Toxicities (DLTs)
- Number of participants with Treatment-emergent Adverse Events (TEAEs)
- Number of participants with TEAEs leading to dose modification or discontinuation
- Interventions
- 8 registered
More on: Advanced solid tumors, INCB161734, cetuximab, retifanlimab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on an alternative treatment considered during KRAS-targeted trial selection.
- 14 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 17 sources about other trials or topics are not included.
- The sources reviewed for this edition do not represent all HCPs or all public discussion. Reposts and quoted redistribution do not establish independent endorsement.
Show all 12 known gaps +Fewer −
- Most cited remarks describe phase 1 INCB161734 or KRAS G12D inhibitor experience in PDAC or CRC without naming NCT06179160. They are treated as contextual commentary on its clinical question, not automatically reassigned as outcomes documented for that registry number.
- Search coverage may miss unnamed trial references or transcription variants, so an issue absent from this report may still have been discussed elsewhere.
- No publication specific to NCT06179160 was identified, no protocol was listed in ClinicalTrials.gov, and no exact INCB161734 label was identified. Some related regulatory material was not assessed; this does not establish approval status.
- Small early cohorts, different pretreatment histories, doses, efficacy denominators and reporting timepoints prevent pooling or conclusions about comparative treatment effects.
- A speaker's use of SAEs for mostly grade 1/2 events, unclear allocation of percentages to cohorts, and qualitative safety descriptions elsewhere limit standardized interpretation of tolerability.
- The statements do not establish mature durability, a validated survival-surrogate role for ctDNA response, or a causal KRAS copy-number resistance mechanism.
- Development forecasts, first-line positioning, best-in-class language and the appendix-cancer proposal are opinions or proposed research directions, not established treatment benefits.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 20, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. INCB161734-101 (NCT06179160): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/incb161734-101-nct06179160
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "INCB161734-101" (NCT06179160), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "incb161734-101-nct06179160". If you cannot make requests, read https://www.erudio.com/reports/incb161734-101-nct06179160.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06179160", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06179160 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/incb161734-101-nct06179160.json
curl https://www.erudio.com/reports/incb161734-101-nct06179160.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "incb161734-101-nct06179160" })release 7e2ce92164533c68626f4bf382b671ec14e6b84af323b4cf4d5a6ff9f8b10512
Questions
How much does the INCB161734-101 report cost?
One edition costs $750 (Focused · 32 verified statements · 16 from 9 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the INCB161734-101 report cover?
32 statements from 18 sources (3 videos, 15 posts), 16 of them from 9 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the INCB161734-101 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "incb161734-101-nct06179160" }) previews it and create_order({ "report": "incb161734-101-nct06179160", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the INCB161734-101 report?
Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.